Germany
· Delayed Price · Currency is EUR Formycon AG Company Description
Formycon AG, a biotechnology company, develops biosimilar drugs in Germany and Switzerland.
It provides FYB201, a biosimilar candidate for Lucentis, an ophthalmic drug used in the treatment of neovascular age-related macular degeneration and other serious retinal diseases, including diabetic macular edema, choroidal neovascularization, proliferative diabetic retinopathy, and macular edema under the Ranivisio, Ongavia, Cimerli, Ranpoto, Uptera, and Ravegza names.
The company’s pipeline includes FYB202, a biosimilar candidate for Stelara used in the treatment of Psoriasis, Crohn’s disease, and ulcerative colitis which has completed the Phase III clinical trial; and FYB203, a biosimilar candidate for Eylea that treats ophthalmology related diseases, including neovascular age-related macular degeneration that has completed Phase III clinical trials.
It is also developing FYB206, a biosimilar candidate for Keytruda, for the treatment of immuno-oncology diseases; and FYB207, a SARS-CoV-2 blocker, an antiviral drug for the treatment of COVID-19.
The company was formerly known as Nanohale AG and changed its name to Formycon AG in 2012. Formycon AG was founded in 1999 and is headquartered in Planegg, Germany.
| Country | Germany |
| Founded | 1999 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 238 |
| CEO | Stefan Glombitza |
Contact Details
Address: Fraunhoferstrasse 15 Planegg, 82152 Germany | |
| Phone | 49 89 864 667 100 |
| Website | formycon.com |
Stock Details
| Ticker Symbol | FYB |
| Exchange | Deutsche Börse Xetra |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| ISIN Number | DE000A1EWVY8 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Stefan Glombitza | Chief Executive Officer and Member of Executive Board |
| Dr. Friedrich-Wilhelm Steinweg | Co-Founder |
| Dr. Nicolas Combe Ph.D. | Co-Founder |
| Enno Spillner | Chief Financial Officer and Member of Management Board |
| Dr. Andreas Seidl | Chief Scientific Officer and Member of Executive Board |
| Nicola Mikulcik | Chief Business Officer and Member of Executive Board |
| Sabrina Muller | Director of Investor Relations and Corporate Communications |